FDA Approves Atezolizumab Again for mNSCLC

08:42 EST 4 Dec 2019 | Medscape

The US Food and Drug Administration approved the immunotherapy as initial treatment of metastatic nonsquamous non-small cell lung cancer (mNSCLC).
Medscape Medical News

Original Article: FDA Approves Atezolizumab Again for mNSCLC


More From BioPortfolio on "FDA Approves Atezolizumab Again for mNSCLC"

Quick Search

Relevant Topics

Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...